MOLN

Molecular Partners AG develops DARPin therapeutics, a novel class of custom-built drugs aimed at treating serious diseases, including cancer. The company leverages its in-house expertise in DARPin design and development, collaborating with various partners to create a broad pipeline of therapeutics. Its operations focus on addressing high unmet medical needs, and it serves healthcare providers and patients across multiple geographies.